Probiodrug’s new preclinical data showed that PQ912 demonstrated efficacy in Huntington’s disease (HD) in an animal model. Subject to further preclinical work, PQ912 could be fast-tracked to the clinic, which would diversify Probiodrug’s R&D pipeline with a new indication. Much will depend on the outcome of the company’s milestone clinical Phase IIa SAPHIR trial with PQ912 for Alzheimer’s disease (AD) with the data readout shortly. PQ912 is a first-in-class s
12 Apr 2017
Early PQ912 data for Huntington's; AD data soon
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Early PQ912 data for Huntington's; AD data soon
Vivoryon Therapeutics N.V. (VVY:AMS) | 0 0 0.0%
- Published:
12 Apr 2017 -
Author:
Dr Jonas Peciulis -
Pages:
6
Probiodrug’s new preclinical data showed that PQ912 demonstrated efficacy in Huntington’s disease (HD) in an animal model. Subject to further preclinical work, PQ912 could be fast-tracked to the clinic, which would diversify Probiodrug’s R&D pipeline with a new indication. Much will depend on the outcome of the company’s milestone clinical Phase IIa SAPHIR trial with PQ912 for Alzheimer’s disease (AD) with the data readout shortly. PQ912 is a first-in-class s